Clofibrate acutely reverses saline-induced endothelial dysfunction: role of calcium-activated potassium channels.
BACKGROUND
Endothelium-dependent vascular relaxation is impaired in various disease states including hypertension.


METHODS
We investigated whether a single bolus dose of clofibrate could rapidly reverse saline-induced endothelial dysfunction, in vivo, in salt-loaded Sprague-Dawley (S-D) rats. S-D rats, 5 weeks of age, were divided into two groups. One group served as a control (Con) and was given tap water; the other group (Sal) was given normal saline (0.9% NaCl) ad libitum for 3 weeks.


RESULTS
Mean arterial pressure (MAP) was significantly higher (138 +/- 2 nu 112 +/- 2 mm Hg, P < .001), whereas the total plasma nitrite/nitrate levels were lower (1.7 +/- 0.3 v 2.8 +/- 0.2 micromol/L, P < .05) in Sal. At this time, endothelial function was assessed in vivo. Sal rats had decreased hypotensive responses to acetylcholine (ACh) but maintained normal responses to sodium nitroprusside. The ACh-induced hypotensive response was significantly inhibited by the nitric oxide synthase inhibitor, N(G)-nitro-l-arginine methyl ester (L-NAME, 100 mg kg(-1) intraperitoneally [ip]) only in Con rats. Clofibrate (Clof, 200 mg kg(-1) ip) did not change blood pressure but increased ACh-induced hypotensive responses only in Sal, an effect that was abolished by subsequent administration of apamin (Apa, 50 microg kg(-1) iv) and charybdotoxin (ChTx, 50 microg kg(-1) iv). Apa+ChTx blocked responses to ACh in Con and Sal, as expected. A single dose of clofibrate (200 mg kg(-1) ip), given subsequently to Apa+ChTx, restored responses to ACh in both the Con and Sal groups, again without affecting baseline MAP.


CONCLUSIONS
Clofibrate has an acute salutary effect on endothelium-dependent vasodilation in saline-treated rats, probably mediated through vascular calcium-activated potassium channels and independent of an antihypertensive effect.
Sankaralingam
Sowndramalingam
S
Department of Pharmacology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Desai
Kaushik M
KM
Wilson
Thomas W
TW
D000109:Acetylcholine; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001030:Apamin; D001795:Blood Pressure Determination; D018999:Charybdotoxin; D002994:Clofibrate / Q000494:pharmacology*; D007022:Hypotension / Q000139:chemically induced / Q000378:metabolism; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D024681:Potassium Channels, Calcium-Activated / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012965:Sodium Chloride; D014664:Vasodilation / Q000187:drug effects* / Q000502:physiology
D000924:Anticholesteremic Agents; D024681:Potassium Channels, Calcium-Activated; D018999:Charybdotoxin; D001030:Apamin; D009569:Nitric Oxide; D012965:Sodium Chloride; D002994:Clofibrate; D000109:Acetylcholine